McCormick Deal Adds Cash, But Unilever Valuation Stays Stretched

What happened

Unilever's sale of its food business to McCormick for $15.7 billion and a 9.9% stake injects significant cash, enabling buybacks and reinvestment in higher-growth areas like Beauty & Wellbeing. The deal reinforces portfolio simplification, a key pillar of its Growth Action Plan. However, underlying sales growth remains modest at 3-4%, and the company is early in a complex transformation involving an Ice Cream demerger and €800m productivity programme. At ~32x trailing earnings, the stock trades well above a DCF-derived intrinsic value of ~$43, suggesting limited margin of safety. While the food divestiture improves focus and capital flexibility, execution must prove the remaining portfolio can deliver superior growth.

Implication

The McCormick transaction provides $15.7B in cash, reducing balance sheet risk and funding buybacks that could support the stock. However, the core investment proposition depends on Unilever's ability to reinvigorate organic growth and expand margins. Until concrete evidence of market share gains and margin improvement emerges, upside is capped by high expectations. Value investors should monitor Q2 results for volume trends and Ice Cream demerger costs; a meaningful pullback would offer a better entry point.

Thesis delta

The food deal is a modest positive, sharpening Unilever's focus and providing cash to return to shareholders. However, it does not address key valuation concerns: sluggish top-line growth and a rich multiple. The thesis shifts from purely cautious to cautiously neutral, but the sell bias due to overvaluation remains intact.